Back to search

Article

Distinct prostate cancer neuroendocrine subtypes predict prognosis and guide personalized prostate-specific membrane antigen-targeted therapy

2024-09-30

Abstract excerpt

<h4>Background and Objective</h4> Second-generation hormonal therapy inhibits castration-resistant prostate cancer (CRPC), but the tumor eventually recurs as neuroendocrine prostate cancer (NEPC) and turns lethal. Differentiating lineage plasticity that contributed to distinct NEPC subtypes aids in advancing treatments, particularly the recent FDA-approved 177 Lu-PSMA-617 radiopharmaceutical therapy. <h4>Method...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1028d7f2-c4ac-5b24-8fed-42b84a6506a7
DOI
10.1101/2024.09.28.615561
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Distinct prostate cancer neuroendocrine subtypes predict prognosis and guide personalized prostate-specific membrane antigen-targeted therapyDOI 10.1101/2024.09.28.615561
Select a neighboring publication to make it the new centre.